C4 Therapeutics is a clinical-stage biotech company focused on developing protein degradation therapies for cancer and inflammatory diseases. Its main experimental treatment, Cemsidomide, targets specific proteins in multiple myeloma and has completed early-stage testing; the company is also advancing CFT8919 for certain lung cancers and pursuing additional candidates in inflammation and neurological conditions. The firm has research partnerships with Roche, Betta Pharmaceuticals, and Merck, including a collaboration on antibody-degrader combinations for cancer.

entry readiness 63 · MODERATE · exit proximity 0

Value area 3.28–4.60 · 70% of 120d volume overhead · heavy supply